Anixa biosciences announces approval of protocol amendment for ovarian cancer car-t clinical trial

Amendment expands the potential benefits of car-t therapy allowing a second dose and includes more ovarian cancer histologies san jose, calif. , feb. 18, 2025 /prnewswire/ --  anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner moffitt cancer center ("moffitt"), has received approval for an amendment to the protocol governing its ongoing clinical trial using car-t therapy for the treatment of ovarian cancer (nct05316129).
CAR Ratings Summary
CAR Quant Ranking